{"id":"W2578172276","doi":"10.1182/blood.v118.21.1876.1876","title":"Integrated Safety From Phase 2 Studies of Monotherapy Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (MM): An Updated Analysis","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Carfilzomib; Bortezomib; Multiple myeloma; Medicine; Proteasome inhibitor; Internal medicine; Refractory (planetary science); Clinical trial; Renal function; Adverse effect; Phases of clinical research; Urology; Pharmacology; Oncology; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01514051,0.0007206945,0.002541078,0.001616577,0.000286575,0.002275109,0.0007266544,0.000804951,0.002109543],"category_scores_gemma":[0.01249353,0.000449005,0.003813273,0.002414426,0.0003308264,0.001259114,0.0008052507,0.001622078,0.0004006162],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001158361,"about_ca_system_score_gemma":0.001348681,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006305514,"about_ca_topic_score_gemma":0.001720237,"domain_scores_codex":[0.9924015,0.00347215,0.001052935,0.0006580679,0.002094143,0.0003212468],"domain_scores_gemma":[0.9756134,0.009945051,0.009297947,0.001444411,0.002669349,0.001029904],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1285171,0.001066305,0.3402981,0.005620263,0.05290313,0.0004309364,0.0004677669,0.005352888,0.01704123,0.0004635869,0.01420841,0.4336303],"study_design_scores_gemma":[0.01705416,0.03928257,0.8650786,0.0008511288,0.03893552,0.001828103,0.0001662154,0.00254047,0.004552403,0.0006104156,0.02897129,0.0001291878],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8483799,0.1007552,0.005440305,0.001896086,0.0001812201,0.001851275,0.02767449,0.0003227195,0.0134989],"genre_scores_gemma":[0.952199,0.01567837,0.002829602,0.001812518,0.0004057482,0.0006778528,0.02496244,0.000140837,0.001293607],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01514051,"threshold_uncertainty_score":0.08007169,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03563666292711026,"score_gpt":0.3026075490250956,"score_spread":0.2669708860979854,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}